AHA Scientific Sessions 2023 Late-Breaking Science Coverage

Published: 30 October 2023

  • Views:

    Views Icon 2244
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Stay up-to-date with the latest data in cardiovascular science with the help of renowned experts and emerging voices who offer concise summaries, in-depth discussions, and critical reviews to keep you informed.

 

In their regular View from the Thoraxcenter series, Prof Van Mieghem and Dr Daemen provide valuable insights into the most anticipated trials of AHA 23. With their keen awareness of cardiovascular innovation, they offer concise perspectives on late-breaking data.

 

Dr Harriette Van Spall returns with her Late-breaker Discussion series featuring ground-breaking research presented at Scientific Sessions. Join her and lead investigators as they discuss methodology, results, and impact on patient care.

 

Watch our Expert interviews for late-breaking science methodology, results and implications for practice and research in under 10 minutes.

 

Delve into the personal motivations of some of the investigators, and gain valuable insights and advice for early career researchers in our Behind the Heart series. These short videos offer an opportunity to look beyond scientific achievements and connect on a more personal level.

More from this programme

Part 1

View from the Thoraxcenter

In their regular View from the Thoraxcenter series, Prof Van Mieghem and Dr Daemen provide valuable insights into the most anticipated trials of AHA 23. 

Part 2

Late-Breaker Discussions with Harriette Van Spall

Dr Harriette Van Spall, recipient of 2022's AHA Dr. Nanette K. Wenger Award, returns with her Late-breaker Discussion series featuring ground-breaking research presented at Scientific Sessions. Join her and lead investigators as they discuss methodology, results, and impact on patient care.

About the episode

AHA 2023 — We are joined by Dr Alexander Fanaroff (Penn Medicine, US) to discuss the findings from a cluster randomised trial of automated referral to centralised pharmacy services for evidence-based statin initiation in high-risk patients.

Gaps have been observed in evidence-based statin prescriptions, where more than 50% of US adults with an indication for atherosclerotic cardiovascular disease are not prescribed statins at the guideline-recommended intensity. Where physicians have limited time to cover preventative needs in-office visits, pharmacists could be used to increase statin prescriptions in appropriate patients.

The SUPER LIPID program aims to test two strategies for the integration of centralised pharmacy services for lipid management into clinician workflow; an interruptive pop-up notification strategy, and a non-visit based asynchronous strategy. Two parallel clinical trials were performed in 10 internal medicine and family medicine clinics in Philadelphia.

Findings suggested that an asynchronous strategy increased prescriptions of any statin by 16% as compared to standard care, and appropriate dose statin by 17%. The interruptive notification strategy had a smaller effect on statin prescriptions, and no effect on appropriate dose prescription, suggesting that a centralised asynchronous model could be an effective approach to increasing statin prescription for high-risk patients. 

Questions:

  1. What is the reasoning behind this trial?
  2. What was the patient population and study design?
  3. What are the key findings?
  4. What are your take-home messages?
  5. Were there any unexpected or surprising results in the trial?
  6. What are the next steps?

Recorded on-site at AHA Scientific Sessions 2023, Philadelphia.

Interviewer: Mirjam Boros
Editor: Jordan Rance
Video Specialists: Dan Brent, Mike Knight, Tom Green

Faculty Biographies

Alexander Fanaroff

Alexander Fanaroff


Dr. Alexander Fanaroff, MD, MHS, is an accomplished interventional cardiologist and Assistant Professor of Medicine within the Division of Cardiology at the University of Pennsylvania. His extensive medical education includes completion of medical school, an internal medicine residency, a cardiology fellowship, and an interventional cardiology fellowship, all at Duke University. Dr. Fanaroff furthered his expertise by obtaining an MHS in clinical research from the Duke/NIH Clinical Research Training Program during a two-year research fellowship at the Duke Clinical Research Institute.

Dedicated to advancing cardiovascular care, Dr. Fanaroff's research endeavors focus on identifying and addressing inefficiencies, variations, and barriers in cardiovascular care delivery. He actively develops solutions to enhance patient and clinician behavior, implementing and testing these interventions through pragmatic clinical trials. His specific interests lie in promoting physical…

View full profile

Comments

You must be to comment. If you are not registered, you can register here.